经皮雌二醇在前列腺癌雄激素抑制中的长期心血管结局:随机PATCH试验项目
PATCH试验为2/3期随机多中心研究,纳入1694例局部晚期或转移性前列腺癌男性,比较经皮雌二醇(tE2)贴片与LHRHa的长期心血管结局。tE2组男性乳房发育更常见(86% vs 38%),LHRHa组潮热更常见(86% vs 35%)。经皮雌二醇可作为前列腺癌雄激素抑制的考虑选项。
要点
- tE2组89例心血管事件中30例(34%)发生在停药或换用LHRHa后3个月以上。
- 1个月时tE2组去势率83% vs LHRHa组65%,3个月时均为93%。
适用人群与场景
- 局部晚期或转移性前列腺癌男性,来自英国52个研究中心,随机分配至LHRHa或tE2贴片。
诊断标准与关键阈值
- 心血管事件包括心力衰竭、急性冠脉综合征、血栓栓塞性卒中及其他血栓栓塞事件,经预设标准和源数据确认。
- 无尸检报告的猝死若符合则纳入心血管事件分析。
处置流程与药物剂量
- LHRHa组:按当地实践给予LHRHa。
- 原文未提及具体LHRHa药物、剂量及给药方案。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的红旗征。
研究设计与关键结果
- PATCH为无缝2/3期随机多中心试验,2007年8月14日至2019年7月30日纳入1694例,LHRHa组790例,tE2组904例。
- tE2组89例心血管事件中30例(34%)发生在停药或换用LHRHa后3个月以上。
证据类型、等级与局限
- 证据类型:随机、多中心、无缝2/3期试验项目(PATCH),适应设计。
对床旁实践的改变
- 对于需要雄激素抑制的前列腺癌患者,经皮雌二醇可作为LHRHa之外的选择,因长期心血管结局无显著差异。
- 使用tE2需告知患者男性乳房发育发生率高(86%),LHRHa则潮热更常见(86%)。
- tE2治疗期间及停药后3个月以上仍需监测心血管事件。
指南或共识出处
- 原文未提及具体指南或共识名称;研究由Cancer Research UK和Medical Research Council Clinical Trials Unit at University College London资助。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Androgen suppression is a central component of prostate cancer management but causes substantial long-term toxicity. Transdermal administration of oestradiol (tE2) circumvents first-pass hepatic metabolism and, therefore, should avoid the cardiovascular toxicity seen with oral oestrogen and the oestrogen-depletion effects seen with luteinising hormone releasing hormone agonists (LHRHa). We present long-term cardiovascular follow-up data from the Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
METHODS: PATCH is a seamless phase 2/3, randomised, multicentre trial programme at 52 study sites in the UK. Men with locally advanced or metastatic prostate cancer were randomly allocated (1:2 from August, 2007 then 1:1 from February, 2011) to either LHRHa according to local practice or tE2 patches (four 100 μg patches per 24 h, changed twice weekly, reducing to three patches twice weekly if castrate at 4 weeks [defined as testosterone ≤1·7 nmol/L]). Randomisation was done using a computer-based minimisation algorithm and was stratified by several factors, including disease stage, age, smoking status, and family history of cardiac disease. The primary outcome of this analysis was cardiovascular morbidity and mortality. Cardiovascular events, including heart failure, acute coronary syndrome, thromboembolic stroke, and other thromboembolic events, were confirmed using predefined criteria and source data. Sudden or unexpected deaths were attributed to a cardiovascular category if a confirmatory post-mortem report was available and as other relevant events if no post-mortem report was available. PATCH is registered with the ISRCTN registry, ISRCTN70406718; the study is ongoing and adaptive.
FINDINGS: Between Aug 14, 2007, and July 30, 2019, 1694 men were randomly allocated either LHRHa (n=790) or tE2 patches (n=904). Overall, median follow-up was 3·9 (IQR 2·4-7·0) years. Respective castration rates at 1 month and 3 months were 65% and 93% among patients assigned LHRHa and 83% and 93% among those allocated tE2. 157 events from 145 men met predefined cardiovascular criteria, with a further ten sudden deaths with no post-mortem report (total 167 events in 153 men). 26 (2%) of 1694 patients had fatal cardiovascular events, 15 (2%) of 790 assigned LHRHa and 11 (1%) of 904 allocated tE2. The time to first cardiovascular event did not differ between treatments (hazard ratio 1·11, 95% CI 0·80-1·53; p=0·54 [including sudden deaths without post-mortem report]; 1·20, 0·86-1·68; p=0·29 [confirmed group only]). 30 (34%) of 89 cardiovascular events in patients assigned tE2 occurred more than 3 months after tE2 was stopped or changed to LHRHa. The most frequent adverse events were gynaecomastia (all grades), with 279 (38%) events in 730 patients who received LHRHa versus 690 (86%) in 807 patients who received tE2 (p<0·0001) and hot flushes (all grades) in 628 (86%) of those who received LHRHa versus 280 (35%) who received tE2 (p<0·0001).
INTERPRETATION: Long-term data comparing tE2 patches with LHRHa show no evidence of a difference between treatments in cardiovascular mortality or morbidity. Oestrogens administered transdermally should be reconsidered for androgen suppression in the management of prostate cancer.
FUNDING: Cancer Research UK, and Medical Research Council Clinical Trials Unit at University College London.
参考来源
- Langley RE, Gilbert DC, Duong T, et al. Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. Lancet. 2021. PMID: 33581820. doi:10.1016/S0140-6736(21)00100-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。